Decoy Therapeutics Inc share price logo

Decoy Therapeutics Inc Share Price

NASDAQ: DCOY

$0.67

+0.01

(+2.04%)

Live

as on

Decoy Therapeutics Inc Stock Performance

as on March 4, 2026 at 6:09 am IST

  • Day's Low

    Day's High

    $0.66
    $0.73
    downward going graph

    1.49%

    Downside

    8.96%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    downward going graph

    100.00%

    Downside

    -100.00%

    Upside

    downward going graph

Decoy Therapeutics Inc share price movements today

Previous Close
$0.66
Open
$0.66
Volume
689.1K
Day's Low - High
$0.66 - $0.73

Decoy Therapeutics Inc Historical Returns

1 Month Return
-3.08 %
3 Month Return
0 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

Decoy Therapeutics Inc Stock Fundamentals & Key Indicators

Check Decoy Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$-

EPS (TTM)

0

Dividend Yield

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

Return On Equity TTM

0.00%

Decoy Therapeutics Inc stock Key Stats

Compare market cap, revenue, PE, and other key metrics of Decoy Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
NA$-NANA0.00%

Decoy Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for Decoy Therapeutics Inc Stock has decreased by -84% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-84% versus previous 30 day period

Decoy Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Total Revenue
-
-
-
-
-
Gross Profit
0
0
0
0
0
Operating Income
-1
-1
-1
0
0
EBITDA
-1
-1
-1
0
0
Interest Expense
-
-
-
-
-
Depreciation
0
0
0
0
0
Income Before Tax
0
-1
-1
0
0
Income Tax Expense
-
-
-
-
-
Net Income
0
-1
-1
0
0
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%

Decoy Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
1
1
0
3
5
1
-
-
-
Gross Profit
0
0
0
3
5
1
0
0
0
Operating Income
-39
-34
-22
-8
-7
-12
-31
-12
-5
EBITDA
-39
-34
-21
-8
-7
-12
-22
-12
-5
Interest Expense
-
-
-
-
0
-
-
-
-
Depreciation
-
-
-
-
-
0
0
0
0
Income Before Tax
-39
-34
-21
-6
-7
-12
-31
-12
-5
Income Tax Expense
-
-
-
-
-
-
-
-
-
Net Income
-39
-34
-21
-6
-7
-12
-31
-12
-5
Net Profit Margin
-3907.65%
-2701.74%
-2615.57%
-200.18%
-140.49%
-693.84%
0.00%
0.00%
0.00%

Decoy Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Net Income
-2
0
-1
-1
0
-1
-1
0
0
Operating Cash Flow
-3
-1
-1
-1
-1
0
-1
0
-1
Investing Cash Flow
-
-
-
-
-
-
-
-
0
Financing Cash Flow
0
0
0
0
1
0
0
0
5
Change in Cash
-3
-1
-1
-1
0
0
0
-1
4

Decoy Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
-39
-34
-21
-6
-7
-12
-31
-12
-5
Operating Cash Flow
-32
-27
-23
-11
-10
-10
-17
-12
-4
Investing Cash Flow
-12
24
14
5
0
-
-1
-
-
Financing Cash Flow
0
0
0
3
17
28
1
6
1
Change in Cash
-44
-3
-9
-2
7
18
-17
-6
-3

About Decoy Therapeutics Inc

Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, Inc., is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence (AI) tools alongside high-speed synthesis techniques to design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.
OrganisationDecoy Therapeutics Inc
HeadquartersOne Broadway, Cambridge, MA, United States, 02142
CEOMr. Frederick E. Pierce II
E-voting on sharesClick here to vote

Key Management of Decoy Therapeutics Inc

Name

Title

Mr. Mark J. Rosenblum CPA

Executive VP & CFO

Mr. Frederick E. Pierce II

CEO & Director

Dr. Barbara Hibner Ph.D.

Chief Scientific Officer & Director

Dr. Nadeem Q. Mirza M.D., M.P.H.

Senior Vice President of Clinical Development

Mr. Peter K. Marschel M.B.A., M.S.

Chief Business Officer

FAQs

What is Decoy Therapeutics Inc share price today?

Decoy Therapeutics Inc share price today is $0.67 as on . Decoy Therapeutics Inc share today touched a day high of $0.73 and a low of $0.66.

What is the 52 week high and 52 week low for Decoy Therapeutics Inc share?

Decoy Therapeutics Inc share touched a 52 week high of $ on and a 52 week low of $ on . Decoy Therapeutics Inc stock price today i.e. is trending at $0.67,which is -Infinity% down from its 52 week high and Infinity% up from its 52 week low.

How to invest in Decoy Therapeutics Inc Stock (DCOY) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Decoy Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Decoy Therapeutics Inc Shares that will get you 2.2388 shares as per Decoy Therapeutics Inc share price of $0.67 per share as on March 4, 2026 at 12:39 am IST.

What is the minimum amount required to buy Decoy Therapeutics Inc Stock (DCOY) from India?

Indian investors can start investing in Decoy Therapeutics Inc (DCOY) shares with as little as ₹92.074 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹920.74 in Decoy Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Decoy Therapeutics Inc share’s latest price of $0.67 as on March 4, 2026 at 12:39 am IST, you will get 14.9254 shares of Decoy Therapeutics Inc. Learn more about fractional shares .